Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Pancreas ; 49(10): 1372-1377, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33122527

RESUMEN

OBJECTIVES: The multidrug regimen with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) is widely used for recurrent pancreatic cancer after pancreatic resection. However, there are concerns about severe toxicities and poor tolerability of FOLFIRINOX in these patients because some suffer from surgery-associated malnutrition, weight loss, and diabetes mellitus. We evaluated the toxicity and tolerability of FOLFIRINOX in these patients. METHODS: This study was conducted as a secondary analysis of the Japan Adjuvant Study Group of Pancreatic Cancer 06 study, which was a multicenter observational study of FOLFIRINOX for pancreatic cancer in Japan. The toxicity and tolerability of FOLFIRINOX in recurrent disease correlated with those of both the locally advanced and the metastatic disease group. RESULTS: The major grades 3 and 4 toxicities observed in the recurrent and locally advanced or metastatic disease groups were neutropenia (68% vs 63%), febrile neutropenia (4% vs 15%, P = 0.007), thrombocytopenia (4% vs 3%), diarrhea (4% vs 8%), and sensory neuropathy (0% vs 2%). The dose modification and relative dose intensity did not differ markedly between the groups. CONCLUSIONS: The toxicity and tolerability of FOLFIRINOX for recurrence after pancreatic resection were similar to those for locally advanced or metastatic disease with appropriate patient selection and dose modifications.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Recurrencia Local de Neoplasia , Pancreatectomía , Neoplasias Pancreáticas/terapia , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Femenino , Fluorouracilo/efectos adversos , Fluorouracilo/uso terapéutico , Humanos , Irinotecán/efectos adversos , Irinotecán/uso terapéutico , Japón , Leucovorina/efectos adversos , Leucovorina/uso terapéutico , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Oxaliplatino/efectos adversos , Oxaliplatino/uso terapéutico , Pancreatectomía/efectos adversos , Neoplasias Pancreáticas/patología , Factores de Tiempo , Resultado del Tratamiento
2.
Radiology ; 292(2): 489-498, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31161974

RESUMEN

Background Interstitial lung abnormalities (ILAs) are present at CT in about 10% of individuals undergoing lung cancer screening. The relationship between histologic findings of ILAs and their influence on patient prognosis remains unknown. Purpose To evaluate the percentage of ILAs at preoperative CT, as measured by radiologists and a computer-aided detection (CAD) software, as a predictor of disease-free survival in patients with lung cancer. Materials and Methods This retrospective study evaluated 217 consecutive patients who underwent complete resection of lung cancer from April 2010 to December 2015. Two radiologists, blinded to the patients' clinical information, scored percentage fibrosis extent and determined whether ILAs and the usual interstitial pneumonia (UIP) pattern were present. They assessed ILA progression at follow-up CT. Two pathologists determined the presence of an UIP pattern. Percentage fibrosis extent was also measured by using CAD. Binary logistic regression analysis was performed to determine whether the CAD percentage fibrosis extent was associated with ILA at CT. Multivariable Cox regression analysis was used to evaluate the significance of CAD percentage fibrosis extent as a predictor of prognosis. Results The radiologists classified 47 patients with ILAs and 24 patients with a UIP pattern at chest CT. The pathologists detected a UIP pattern in 25 patients. CT abnormalities showed progression over a 2-year period in all patients with histologic evidence of UIP. After adjustment for age, sex, and smoking index, the CAD percentage fibrosis extent was independently associated with ILA (odds ratio: 3.1; 95% confidence interval [CI]: 2.1, 4.7; P < .001). After adjustment for age, forced expiratory volume in 1 second (percentage predicted) radiologist-assessed percentage fibrosis extent, and pathologic stage, CAD percentage fibrosis extent was independently associated with worse disease-free survival (hazard ratio: 1.3; 95% CI: 1.1, 1.6; P < .001). Conclusion Greater computer-aided detection percentage fibrosis extent at preoperative CT independently predicted worse disease-free survival in patients with lung cancer. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Goo in this issue.


Asunto(s)
Procesamiento de Imagen Asistido por Computador/métodos , Neoplasias Pulmonares/complicaciones , Fibrosis Pulmonar/complicaciones , Fibrosis Pulmonar/diagnóstico por imagen , Tomografía Computarizada por Rayos X/métodos , Adulto , Anciano , Anciano de 80 o más Años , Supervivencia sin Enfermedad , Femenino , Humanos , Pulmón/diagnóstico por imagen , Pulmón/cirugía , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Cuidados Preoperatorios/métodos , Estudios Retrospectivos
3.
Endocr J ; 53(6): 811-8, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17001112

RESUMEN

We found that androgen and IGF-I up-regulated IGFBP-5 mRNA in androgen-responsive normal human fibroblast, which was blocked by co-treatment with 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole, but not cycloheximide. IGFBP-5 promoter activity was stimulated by androgen. Nuclear run-on assay revealed that IGFBP-5 transcripts were increased in response to androgen, which was not enhanced by co-addition of IGF-I. These results collectively indicate that IGFBP-5 synthesis is regulated by androgen through transcriptional mechanisms in androgen responsive cells.


Asunto(s)
Fibroblastos/efectos de los fármacos , Proteína 5 de Unión a Factor de Crecimiento Similar a la Insulina/biosíntesis , Receptores Androgénicos/metabolismo , Testosterona/farmacología , Transcripción Genética/efectos de los fármacos , Células Cultivadas , Fibroblastos/metabolismo , Semivida , Humanos , Proteína 5 de Unión a Factor de Crecimiento Similar a la Insulina/genética , Factor I del Crecimiento Similar a la Insulina/farmacología , Regiones Promotoras Genéticas , ARN Mensajero/metabolismo , Activación Transcripcional
4.
Endocr J ; 53(5): 639-45, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16902264

RESUMEN

Congenital generalized lipodystrophy (CGL) is a disease characterized by generalized lack of body fat, insulin resistance, hypertriglyceridemia, and fatty liver. We studied the long-term effects of recombinant human insulin-like growth factor I (rhIGF-I) treatment on glucose and lipid metabolism and the growth in a patient with CGL. During rhIGF-I treatment, the serum triglyceride level was maintained almost within the normal range, and the plasma glycosylated hemoglobin A1c (HbA1c) levels were maintained under 8.0% (5.8%-7.9%). Thus, rhIGF-I treatment was effective in lowering glucose and triglyceride levels over the long-term in a CGL patient. However, it was difficult to suppress the patient's voracious appetite. Although serum total IGF-I levels were extremely high (1000-1700 ng/ml), growth was not accelerated after the start of rhIGF-I treatment, likely because of normal IGF binding protein 3 (IGFBP-3) levels. During rhIGF-I treatment, the patient developed a recurrence of mild hypertrophic cardiomyopathy and a mild elevation of intraocular pressure.


Asunto(s)
Glucosa/metabolismo , Crecimiento y Desarrollo/efectos de los fármacos , Factor I del Crecimiento Similar a la Insulina/uso terapéutico , Metabolismo de los Lípidos/efectos de los fármacos , Lipodistrofia Generalizada Congénita/tratamiento farmacológico , Adolescente , Proteínas Sanguíneas/análisis , Femenino , Prueba de Tolerancia a la Glucosa , Hemoglobina Glucada/análisis , Humanos , Factor I del Crecimiento Similar a la Insulina/efectos adversos , Factor I del Crecimiento Similar a la Insulina/análisis , Proteínas Recombinantes/uso terapéutico , Tiempo
5.
Pituitary ; 7(3): 165-169, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-16010454

RESUMEN

We report the usefulness of a highly sensitive immune complex transfer enzyme immunoassay (ICT-EIA) to detect human chorionic gonadotropin (HCG)-beta and thereby the onset of neurohypophyseal germinoma in its active phase. A 14-year-old girl exhibiting arrested puberty was diagnosed with neurohypophyseal germinoma following observation for two years. This patient initially showed no signs of diabetes insipidus (DI). While ICT-EIA indicated concentrations of HCG-beta higher than normal in cerebrospinal fluid (CSF) and serum, the results obtained with conventional methods were negative. ICT-EIA was also useful to assess the efficacy of treatment.


Asunto(s)
Biomarcadores de Tumor/análisis , Gonadotropina Coriónica Humana de Subunidad beta/análisis , Germinoma/diagnóstico , Técnicas para Inmunoenzimas , Neurohipófisis , Neoplasias Hipofisarias/diagnóstico , Adolescente , Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/líquido cefalorraquídeo , Gonadotropina Coriónica Humana de Subunidad beta/sangre , Gonadotropina Coriónica Humana de Subunidad beta/líquido cefalorraquídeo , Femenino , Germinoma/sangre , Germinoma/líquido cefalorraquídeo , Humanos , Imagen por Resonancia Magnética , Neurohipófisis/patología , Neoplasias Hipofisarias/sangre , Neoplasias Hipofisarias/líquido cefalorraquídeo , Neoplasias Hipofisarias/tratamiento farmacológico , Sensibilidad y Especificidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...